Zelboraf (vemurafenib tablets) — Cigna
Thyroid Carcinoma, Differentiated
Initial criteria
- Patient age ≥ 18 years
- Patient has differentiated thyroid carcinoma (papillary, follicular, or oncocytic)
- Patient has disease that is refractory to radioactive iodine therapy
- Patient has BRAF mutation-positive disease
Approval duration
1 year